Navigation Links
Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
Date:3/1/2011

RICHMOND, Calif., March 1, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 10:15 am ET on Tuesday, March 8, 2011 at the Cowen and Company 31st Annual Health Care Conference which will be held in Boston.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developin
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
2. Sangamo BioSciences Announces Presentation at the 13th Annual BIO CEO & Investor Conference
3. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
4. Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
6. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
7. Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast
8. Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
10. Sangamo Announces Closing of Common Stock Offering
11. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Veran Medical Technologies, a U.S. ... positive, cost-effective final results for the initial ... SPiNPerc endobronchial percutaneous biopsy study results support ... biopsy when a traditional bronchoscopic method is ... positive financial outcomes when more can be ...
(Date:7/10/2014)...  Major advances in radiation therapy and radiosurgery ... in a three-day Oncology Summit taking place in ...  Renowned national and international cancer experts from seven countries ... knowledge on modern technologies making treatment for cancer ... The Summit will address a wide spectrum ...
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... YORK, Sept. 8, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0611073/Global-Intravascular-Ultrasound-IVUS-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_I This ... Ultrasound (IVUS) in US$ Million by the ...
... Pa., Sept. 8, 2011 Auxilium Pharmaceuticals, Inc. ... company, today announced additional three year recurrence data ... Long-term Evaluation of Success Study (CORDLESS) for XIAFLEX ... of adult Dupuytren,s contracture patients with a palpable ...
Cached Medicine Technology:Global Intravascular Ultrasound (IVUS) Industry 2Global Intravascular Ultrasound (IVUS) Industry 3Global Intravascular Ultrasound (IVUS) Industry 4Global Intravascular Ultrasound (IVUS) Industry 5Global Intravascular Ultrasound (IVUS) Industry 6Global Intravascular Ultrasound (IVUS) Industry 7Global Intravascular Ultrasound (IVUS) Industry 8Global Intravascular Ultrasound (IVUS) Industry 9Global Intravascular Ultrasound (IVUS) Industry 10Global Intravascular Ultrasound (IVUS) Industry 11Global Intravascular Ultrasound (IVUS) Industry 12Global Intravascular Ultrasound (IVUS) Industry 13Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 2Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 3Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 4Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 5Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 6Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 7Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 8Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting 9
(Date:7/13/2014)... Advanced boilers are preferred over ... of fossil fuels, produce high-capacity power, emit fewer ... global warming and climate change concerns, many countries ... gas emissions and pollutants coming from fossilfuel-based power ... global advance boilers market., The global power rental ...
(Date:7/13/2014)... 13, 2014 According to a ... Computing Market by Component (processor, GPU, DSP, connectivity), ... Medical), and Geography - Forecast and Analysis to ... Processing & Computing Market is expected to reach ... of 20.75% from 2014 to 2020. , Browse ...
(Date:7/13/2014)... A Massachusetts couple who have done ... associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) finally ... regulators, as they presented poignant testimony on the second ... (FDA) advisory panel meeting convened to address the issue, ... Democrat and Chronicle, Dr. Hooman Noorchashm and his wife, ...
(Date:7/13/2014)... 2014 The Pearland, Texas location of The ... from four months to 12 years of age that offers ... birthday parties and Summer Camps, is now under new ownership. ... Pearland after spending over six years at The Little ... Director. , Berry has over ten years of experience ...
(Date:7/13/2014)... York, New York (PRWEB) July 13, 2014 ... lawsuits ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson ... litigation’s second bellwether trial, which is expected to get ... Order issued in the U.S. District Court, Southern District ... Conference will be held on August 7, 2014 at ...
Breaking Medicine News(10 mins):Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4
... WASHINGTON, Sept. 25 The following was,released today by ... tonight, the House of Representatives is expected to vote ... for,illegal immigrants and uses budgetary gimmicks to capture new ... private insurance and,onto government-run health care. Here,s just a ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... services, today announced that it has,filed a universal ... (SEC) for the periodic offering and sale of ... common stock and warrants,after the SEC declares the ...
... CHARLOTTESVILLE, VA (September 25, 2007) Birds, fish and ... generally cannot: re-grow damaged or lost inner ear hair ... deficiencies and disabling balance problems in an estimated 250 ... treatments, research and development efforts have been hindered by ...
... Under Medicare Creates Two-Tiered System of Cancer Care ... Face Avoidable Blood Transfusions, HOUSTON, Sept. 25 ... over 1,100 oncologists across the,country, today expressed "deep ... for Medicare and Medicaid Services (CMS) -- the ...
... American Society of,Transplantation (AST) Past President Jeffrey ... Representatives, Information, Policy, Census and,National Archives Subcommittee of ... subcommittee to use public policy and,technology to strengthen ... Dr. Crippin, over 97,000 individuals are awaiting a,life-saving ...
... Sept. 25 The HealthCentral Network,Inc. ... an author,and psychotherapist who has asthma and ... expert. Miller, dubbed,"Allergic Girl", first gained online ... Nuts", which catalogues her daily challenges with ...
Cached Medicine News:Health News:'Compromise' SCHIP Deal Substitutes Ideology for Common Sense 2Health News:Gentiva(R) Health Services Files Universal Shelf Registration Statement 2Health News:Gentiva(R) Health Services Files Universal Shelf Registration Statement 3Health News:Study expected to boost research for hearing and balance therapies 2Health News:Cancer Doctors Across America 'Stunned' at Government's Ruling Restricting Anemia Management Protocols for Cancer Patients, Call Ruling 'Interference' in Practice of Medicine 2Health News:Cancer Doctors Across America 'Stunned' at Government's Ruling Restricting Anemia Management Protocols for Cancer Patients, Call Ruling 'Interference' in Practice of Medicine 3Health News:American Society of Transplantation's Past President Testifies Before Congress at Forum on Organ Donation 2Health News:Leading Asthma and Allergy Author and Counselor Joins The HealthCentral Network As Expert 2Health News:Leading Asthma and Allergy Author and Counselor Joins The HealthCentral Network As Expert 3
CRP Liquid Conrtols level 3...
Therapeutic Drug Calibrator Series...
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
The AST method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma...
Medicine Products: